Imatinib, a first-generation ABL1 TKI, was approved as first-line therapy following the landmark International Randomized Study of Interferon and STI571 (IRIS trial) for newly diagnosed patients with CML [13]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.